✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Incyte Corp

Common Name
Incyte
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
2,844
Ticker
INCY
Exchange
Nasdaq
Description
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates...

Incyte's GHG Emissions Data Preview

In 2025, Incyte completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Incyte has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2025202420232022-2019
Total Scope 1
8,872a
9,576a
9,351a
Total Scope 2
Market-Based
877a
901a
865a
Location-Based
6,709a
6,516a
6,079a
Total Scope 3
N/A
12,667b
12,924b
Total Scope 1 Revenue Intensity (tCO2e/$M)
1.7257a
2.2578a
2.5303a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=INCY&reporting_period=2025"

Verified Sources Behind Incyte’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Incyte's Responsibility Report 2025
b. Incyte's Responsibility Report 2024

Insights into Incyte's Operational Emissions

In 2025, the total operational greenhouse gas (GHG) emissions of Incyte amounted to 15,581 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2024, the total operational greenhouse gas (GHG) emissions of Incyte decreased by 3.18%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Incyte's Scope 1 Emissions Over Time

201920202021202220232024202502.5 k5 k7.5 k10 ktCO2e-2%+36%+27%+16%+2%-7%
  • Total Scope 1
  • Year-over-Year Change

What are Incyte's Scope 1 emissions?

In 2025, the total Scope 1 emissions of Incyte were 8,872 metric tons of CO₂ equivalent (tCO₂e).a

Has Incyte reduced its Scope 1 emissions over time?

Since 2019, Incyte's Scope 1 emissions have increased by 85.8%, reflecting a rising long-term trend in Scope 1 emissions over time.a

Compared to the previous year (2024), Incyte's Scope 1 emissions decreased by 7.35%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Incyte's Scope 2 emissions?

In 2025, Incyte reported Scope 2 greenhouse gas (GHG) emissions of 877 tCO₂e using the market-based method and 6,709 tCO₂e using the location-based method.a

Has Incyte reduced its Scope 2 emissions over time?

Since 2019, Incyte's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Incyte's emissions have plateaued with no significant change in its energy consumption footprint.a

Compared to the previous year (2024), Incyte's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Incyte's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Incyte use for Scope 2 reporting?

In 2025, Incyte reported its Scope 2 emissions using the market-based method and using the location-based method.a

Incyte's Scope 2 Emissions Over Time

201920202021202220232024202502 k4 k6 k8 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Incyte’s GHG Emissions Intensity Compared to Industry Peers

In 2025, Incyte reported Scope 1 greenhouse gas (GHG) emissions of 8,872 tCO₂e and total revenues of USD 5,141 millions. This translates into an emissions intensity of 1.73 tCO₂e per millions USD.a

Incyte's Scope 1 Emissions Intensity Compared to Peers

2501,00020,000200,000Scope 1 Emissions (tCO2e)201001,0005,00050,000Revenues (Millions of USD)Sino BiopharmaceuticalYear: 2024Scope 1: 18,239 tCO2eRevenue: $M 3,955Scope 1 Intensity: 4.61 tCO2e/$MWuXi Biologics (Cayman)Year: 2024Scope 1: 38,346 tCO2eRevenue: $M 2,559Scope 1 Intensity: 14.99 tCO2e/$MGenmabYear: 2025Scope 1: 758 tCO2eRevenue: $M 586Scope 1 Intensity: 1.29 tCO2e/$MBiontechYear: 2025Scope 1: 2,209 tCO2eRevenue: $M 3,374Scope 1 Intensity: 0.65 tCO2e/$MCelltrionYear: 2024Scope 1: 27,147 tCO2eRevenue: $M 2,424Scope 1 Intensity: 11.20 tCO2e/$MFrontage HoldingsYear: 2023Scope 1: 2,883 tCO2eRevenue: $M 260Scope 1 Intensity: 11.10 tCO2e/$MRecursion PharmaceuticalsYear: 2023Scope 1: 854 tCO2eRevenue: $M 45Scope 1 Intensity: 19.16 tCO2e/$MSarepta TherapeuticsYear: 2023Scope 1: 3,428 tCO2eRevenue: $M 1,243Scope 1 Intensity: 2.76 tCO2e/$MCatalyst PharmaceuticalsYear: 2024Scope 1: 4 tCO2eRevenue: $M 493Scope 1 Intensity: 0.01 tCO2e/$MLegend BiotechYear: 2024Scope 1: 769 tCO2eRevenue: $M 627Scope 1 Intensity: 1.23 tCO2e/$MBio-TechneYear: 2023Scope 1: 3,001 tCO2eRevenue: $M 1,137Scope 1 Intensity: 2.64 tCO2e/$MHalozyme TherapeuticsYear: 2025Scope 1: 1,104 tCO2eRevenue: $M 1,397Scope 1 Intensity: 0.79 tCO2e/$MCytokineticsYear: 2025Scope 1: 294 tCO2eRevenue: $M 88Scope 1 Intensity: 3.34 tCO2e/$MRegeneron PharmaceuticalsYear: 2025Scope 1: 89,990 tCO2eRevenue: $M 14,343Scope 1 Intensity: 6.27 tCO2e/$MVertex PharmaceuticalsYear: 2025Scope 1: 12,296 tCO2eRevenue: $M 12,001Scope 1 Intensity: 1.02 tCO2e/$MIonis PharmaceuticalsYear: 2025Scope 1: 2,615 tCO2eRevenue: $M 944Scope 1 Intensity: 2.77 tCO2e/$MInsmedYear: 2025Scope 1: 2,622 tCO2eRevenue: $M 606Scope 1 Intensity: 4.32 tCO2e/$MModernaYear: 2025Scope 1: 10,463 tCO2eRevenue: $M 1,922Scope 1 Intensity: 5.44 tCO2e/$MFortrea HoldingsYear: 2025Scope 1: 1,418 tCO2eRevenue: $M 2,723Scope 1 Intensity: 0.52 tCO2e/$MBioMarin PharmaceuticalYear: 2022Scope 1: 14,000 tCO2eRevenue: $M 2,096Scope 1 Intensity: 6.68 tCO2e/$MAlnylam PharmaceuticalsYear: 2025Scope 1: 6,785 tCO2eRevenue: $M 3,714Scope 1 Intensity: 1.83 tCO2e/$MIncyteYear: 2025Scope 1: 8,872 tCO2eRevenue: $M 5,141Scope 1 Intensity: 1.73 tCO2e/$M

How does Incyte's GHG emissions intensity compare to its peers?

In 2025, Incyte reported a Scope 1 emissions intensity of 1.73 tCO₂e per millions USD. Compared to the peer group median of 2.77, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Incyte rank on GHG emissions intensity within its industry?

In 2025, Incyte ranked 8 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Incyte is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Want Full Access to Incyte's GHG Emissions Dataset?
Start 30-Day Free Trial